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Investigation of a bicyclo[1. 
ABSTRACT:
We describe the incorporation of a bicyclo[1.1.1]pentane moiety within two known LpPLA2 inhibitors to act as bioisosteric phenyl replacements. An efficient synthesis to the target compounds was enabled with a dichlorocarbene insertion into a bicyclo[1.1.0]butane system being the key transformation. Potency, physicochemical and X-ray crystallographic data were obtained to compare the known inhibitors to their bioisosteric counterparts, which showed the isostere was well tolerated and positively impacted on the physicochemical profile.
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Lipoprotein-associated phospholipase A2 (LpPLA2) or plateletactivating factor acetylhydrolase (PAF-AH) has been extensively studied as a potential therapeutic target for the treatment of atherosclerosis [1] [2] [3] [4] [5] [6] and more recently in other diseases where vascular inflammation may play a role e.g. diabetic macular edema and Alzheimer's disease. 7, 8 A range of epidemiological and genetic evidence suggests that increased LpPLA2 concentration increases the risk of myocardial infarction (MI), ischemic stroke and cardiac death in patients with stable cardiovascular disease (CVD). 1, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] With considerable support for the hypothesis that LpPLA2 is associated with atherosclerosis, a range of inhibitors have been developed, with darapladib, 1 [27] [28] [29] and rilapladib, 2 30 being well studied examples as both compounds have entered clinical trials ( Figure 1 ). 28 It is highly lipophilic (ChromLogD7.4: 6.3) although does however, have good artificial membrane permeability (AMP) of 230 nm/s. In vivo studies have consistently shown inhibition of the hydrolysis of LpPLA2 substrates in rats, dogs, rabbits and pigs. 28 The in vivo effects of 1 include reduced content of lyso-phosphatidylcholines (lyso-PCs) within atherosclerotic lesions, which are pro-inflammatory mediators. 31 Both compounds 1 and 2( Figure  1 ) bind to LpPLA2 in a similar manner with the cyclic amide/ketone mimicking the ester functionality of the enzyme substrates within the oxyanion hole. 32, 33 This blocks the active site where a Ser273, His351 and Asp296 form the catalytic triad and the backbone amide NHs of a Leu153 and Phe274 help to bind the substrate ( Figure 5 ). The remaining functionality occupies lipophilic pockets adjacent to the active site. Compound 2 similarly displays excellent LpPLA2 potency in in vitro assays. Both inhibitors, however, exhibit sub-optimal physicochemical profiles. They have high molecular weights, low aqueous solubility and high property forecast indices (PFI); a risk indicator of developability. 34 Improvement of the physicochemical properties of these compounds is therefore attractive. Methods of achieving this include: introduction of polar functionality; removal of lipophilic groups or replacement of sub-optimal groups, such as aromatic rings with suitable bioisosteres, all of which were postulated to positively impact parameters such as PFI. In this regard we targeted replacement of aromatic rings with saturated isosteres and became interested in the bicyclo[1.1.1]pentane system. There are a paucity of examples of the use of this template as a phenyl bioisostere [35] [36] [37] including an mGluR1 receptor antagonist 3 38,39 and a -secretase inhibitor 4 ( Figure 2) . 40 This is possibly due to the lack of tractable routes to the desired analogues. Despite this, we reasoned it could serve as a useful isostere of the aryl unit in the darapladib chemotype ( Figure 3 ). Accordingly, in this letter we illustrate the successful incorporation of the bicyclo[1.1.1]pentane into both the darapladib and rilapladib structures. The crystal structure of darapladib bound to LpPLA2, solved in-house and comparable to the structure recently published, 33 indicates the internal aromatic of the bi-aryl system acts as a spacer, to allow access to a lipophilic pocket occupied by the trifluoromethylphenyl group. Modeling of the bicyclo[1.1.1]pentane moiety within LpPLA2, and comparison with the X-ray structure of darapladib, confirmed its potential viability as a replacement linker (Figure 4 ). It was envisaged that disrupting the planarity of the biaryl system would improve the physicochemical profile.
There are only two previously reported syntheses of the bicyclo[1.1.1]pentane moiety. 41, 42 These include utilizing a propellane as the key intermediate followed by a photochemical acetylation. 43 Alternatively, addition of a carbene derivative to a bicyclo[1.1.0]butane followed by dechlorination can be employed. 42 The latter was deemed more suitable for large scale chemistry and was therefore exploited in these syntheses. The synthesis of key intermediate 13 commenced with an organometallic addition into the commercially available ketone 6 to furnish 7 as approximately a 2:1 ratio of diastereomers in good yield. Alcohol 7 was converted to the chloride, and subsequent esterification and cyclisation gave intermediate 10 with all steps proceeding in good to excellent yield. 44 The bicyclo[1.1.0]butane derivative 10 was treated with a dichlorocarbene 42 to generate 11 in a yield comparable with literature. Alternative carbene additions, including a Simmons Smith reagent, were investigated, however, these all proved unsuccessful. In a modification to the established process dechlorination of 
Scheme 3 -Synthesis of bioisosteric rilapladib analogue 22
Reagents and conditions: (i) 18, T3P, Et3N, CH2Cl2, rt, 74%; (ii) [Ir(COE)2Cl]2, Et2SiH2, CH2Cl2, rt, 59%; (iii) 21m T3P, Et3N, CH2Cl2, rt, 53%.
With target compound 5 in hand, a comparison of its enzyme potency and physicochemical properties with that of darapladib was undertaken. Data collected included LpPLA2 potency, solubility, ChromLogD7.4 (and associated PFI 34 ), as well as AMP binding. Analogue 5 maintains high potency compared to that of its parent 1 with a pIC50 of 9.4 (1 pIC50 = 10.2). This suggested that the bioisosteric moiety was tolerated within the enzyme. In order to compare the binding mode of the bioisosteric analogue 5 with darapladib, an X-ray crystal structure of 5 in the LpPLA2 protein was generated. 48 The structure, solved at ~1.9 Å resolution, revealed a similar binding mode for both molecules ( Figure 5 ), which is in agreement with the initial molecular modeling (Figure 4 ). The overlay of the two structures reveals that the bicyclo[1.1.1]pentane moiety slightly precludes the adjacent tri-fluorophenyl moiety extending as far towards Leu121 and Phe125, although these residues move slightly towards the inhibitor to fill the void. This sub-optimal occupancy of the pocket could be an important factor in the slight drop-off in potency. Furthermore, the moiety has no effect on the key interactions within the oxyanion hole; retaining the carbonyl to backbone amide NH bonds with Leu153 and Phe274 residues and subsequently blocking the catalytic triad. With the binding mode of both progenitor compound 2 and analogue 5 confirmed, a physicochemical comparison of both was conducted (Table 1) . Analogue 5 showed an improved permeability of 705 nm/s from 230 nm/s 49 and a 9-fold increase in kinetic solubility over darapladib (74 vs. 8 M respectively). However, this was accompanied by an undesired increase in lipophilicity as determined by measured ChromLogD7.4 from 6.3 to 7.0. Calculation of Property Forecast Index, which is a summation of ChromLogD7.4 and number of aromatic rings 34 consequently indicated that the compounds 1 and 5 have equivalent PFIs due to the removal of one aromatic ring. Thermodynamic fasted state simulated intestinal fluid (FaSSIF) solubility was also obtained with analogue 5 exhibiting an approximately 3-fold improvement (>1000 g/mL compared to 399 g/mL). This data is echoed by the comparison of 2 and 22, with 22 displaying improved solubility at pH 7.4 in both kinetic and thermodynamic measures as well as equivalent PFIs. Additionally, low clearance was observed for both 5 and 22 in a human liver microsomal assay, 1.2228 mL/min/g and 0.7607 mL/min/g respectively. These data lend weight to the hypothesis that disrupting molecular planarity 40,50,51 and reducing aromatic ring count 34 can be beneficial to solubility and the overall pharmacokinetic profile.
In summary, the incorporation of the bioisoteric bicyclo[1.1.1]pentane replacement, within LpPLA2 analogues 5 and 22, respectively has been enabled through a challenging synthesis. High potency was maintained for 5 and the binding mode was confirmed by X-ray crystallography.
48 The [1.1.1]bicyclopentane moiety imparts improved physicochemical properties compared to the known inhibitor. This confirms the utility of this group as a phenyl bioisostere in the context of LpPLA2 inhibition.
Supporting Information (7) Staurenghi, G. 
Supporting Information General experimental
Solvents and reagents. Unless otherwise stated, all reactions were carried out under an atmosphere of nitrogen in heat-or oven-dried glassware and using anhydrous solvent. Solvents and reagents were purchased from commercial suppliers and used as received.
Reactions were monitored by thin layer chromatography (TLC) or liquid chromatographymass spectroscopy (LCMS). Heating was conducted using hotplates with DrySyn adaptors.
Chromatography. Thin layer chromatography (TLC) was carried out using plasticbacked 50 precoated silica plates (particle size 0.2 mm). Spots were visualised by ultraviolet (UV) light ( max = 254 nm or 365 nm) and then stained with potassium permanganate solution followed by gentle heating. Flash column chromatography was carried out using the Teledyne ISCO CombiFlash® Rf+ apparatus with RediSep® or GraceResolv™ silica cartridges.
Liquid chromatography mass spectrometry. LCMS analysis carried out using system 1 described below unless otherwise stated as using system 2. Infrared (IR) spectroscopy. Infrared spectra were recorded using a Perkin Elmer Spectrum 1 machine. Absorption maxima (vmax) are reported in wavenumbers (cm −1 ) and are described as strong (s), medium (m), weak (w) and broad (br).
High-resolution mass spectrometry (HRMS).
High-resolution mass spectra were recorded on a Micromass Q-Tof Ultima hybrid quadrupole time-of-flight mass spectrometer, with analytes separated on an Agilent 1100 Liquid Chromatography equipped with a Phenomenex Luna C18 (2) reversed phase column (100 mm x 2.1 mm, 3 µm packing diameter). LC conditions were 0.5 mL/min flow rate, 35 ºC, injection volume 2-5 µL. Gradient elution with (A) H2O containing 0.1% (v/v) formic acid and (B) acetonitrile containing 0.1% (v/v) formic acid. Gradient conditions were initially 5% B, increasing linearly to 100% B over 6 min, remaining at 100% B for 2.5 min then decreasing linearly to 5% B over 1 min followed by an equilibration period of 2.5 min prior to the next injection. Mass to charge ratios (m/z) are reported in Daltons.
Melting points. Melting points were recorded on a Stuart SMP10 melting point apparatus.
Mass directed auto preparation (MDAP).
Mass-directed automated purification was carried out using an H2Os ZQ MS using alternate-scan positive and negative electrospray and a summed UV wavelength of 210-350 nm. Two liquid phase methods were used: • PDB file for compound 5 bound to LpPLA2 available for immediate release upon publication. To 1-bromo-4-(trifluoromethyl)benzene (197 g, 876 mmol) in THF (1000 mL) was added nbutyllithium (2.5M in hexanes) (500 mL, 1250 mmol) at −78 ºC. The reaction was stirred for 2 h before 3-oxocyclobutanecarboxylic acid (50 g, 438 mmol) in THF (250 mL) was added dropwise at −78 ºC. The reaction was allowed to warm to ambient temperature and was stirred for 16 h. The reaction mixture was quenched with saturated NH4Cl solution (200 mL) and basified with 2M NaOH solution (500 mL) and washed with ethyl acetate (700 mL). The layers were separated and the aqueous layer was acidified with 2M HCl solution (1000 mL). The aqueous was extracted with ethyl acetate (1000 mL) which was then dried over Na2SO4 and evaporated under reduced pressure to afford 3-hydroxy-3-(4- 
3-Chloro-3-(4-(trifluoromethyl)phenyl)cyclobutanecarboxylic acid 8
To 3-hydroxy-3-(4-(trifluoromethyl)phenyl)cyclobutanecarboxylic acid (16.18 g, 62.2 mmol) in toluene (300 mL) was added conc. HCl (50 mL, 617 mmol) at ambient temperature and the reaction was sonicated for 7 h. The layers were separated and the aqueous layer was extracted with toluene (2 × 50 mL). The organics were combined and washed with water (2 × 50 mL) and brine (2 × 50 mL). The organics were filtered through a hydrophobic frit and evaporated under reduced pressure to give 3-chloro-3-(4-(trifluoromethyl)phenyl)cyclobutanecarboxylic acid (13.1 g, 46.9 mmol, 75%) as a white solid. The isomers can be separated via the following procedure. The mixture was triturated with hexane and filtered to collect the solid washing with hexane. 35.9 mmol) and HCl (4M in 1,4-dioxane) (45 mL, 180 mmol) in 1,4-dioxane (100 mL) stirred under nitrogen at ambient temperature was added methanol (100 mL, 2472 mmol). The reaction mixture was stirred at ambient temperature for 3 h. Saturated aq. NaHCO3 (20 mL) and ethyl acetate (20 mL) were added and the layers were separated. The aqueous layer was extracted with ethyl acetate (3 × 20 mL) and the combined organics were evaporated under reduced pressure to give methyl 3-chloro-3-(4-trifluoromethyl)phenyl)cyclobutanecarboxylate (10.5 g, 35.9 mmol, quant.) as a pale yellow liquid.
Analogously, the isomers of 9 could be produced using isomerically pure starting materials. To solid sodium hydride (60% dispersion in oil) (8.2 g, 205 mmol) in THF (250 mL) stirred under nitrogen at ambient temperature was added a solution of cis-methyl 3-chloro-3-(4(trifluoromethyl)phenyl)cyclobutanecarboxylate (50 g, 171 mmol) in THF (250 mL) portionwise. The reaction mixture was stirred at ambient temperature for 3 h. To the reaction mixture was added NH4Cl(aq) (100 mL) and ethyl acetate (350 mL) then water (100 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (3 x 50 mL). The organics were combined and dried through a hydrophobic frit. Methyl 3-(4-(trifluoromethyl)phenyl)bicyclo[1.1.0]butane-1-carboxylate (5 g, 19.51 mmol) was dissolved in diethylene glycol dimethyl ether (10 mL) and tetrachloroethylene (PCE) (30 mL) and the reaction mixture was heated to 120 ºC. Solid sodium 2,2,2-trichloroacetate (18.09 g, 98 mmol) was added portionwise over 30 min and the reaction was stirred at 140 ºC for an additional 30 min. Water (100 mL) and CH2Cl2 (100 mL) were added and the layers were separated. The organic layer was washed with brine (10 × 50 mL) and was then filtered through a hydrophobic frit. Added CH2Cl2 (100 mL) and this was washed with brine (5 × 50 mL) and then 5% LiCl(aq) (5 × 50 mL) to remove diethylene glycol dimethyl ether. The organic layer was filtered through a hydrophobic frit and the solvent was removed under reduced pressure to give the crude product. This was purified using column chromatography eluting with 0-20 cyclohexane:TBME. Collected fractions containing product were evaporated under reduced pressure to give methyl 2,2-dichloro-3-(4-(trifluoromethyl)phenyl)bicyclo[1. .78 mmol) in toluene (50 mL). Then tris(trimethylsilyl)silane (TTMSS) (11 mL, 38.9 mmol) was added. The reaction was heated under reflux for 3 h. ACHN (1.9 g, 7.77 mmol) was added portionwise over 4 days with continued heating under reflux. The solvent was removed under reduced pressure and the crude product was purified using column chromatography eluting with 0-20% cyclohexane:TBME. Fractions containing product were impure and these were purified using column chromatography eluting with 0-10% cyclohexane:TBME. Fractions containing product were evaporated under reduced pressure to give methyl 3-(4(trifluoromethyl)phenyl)bicyclo[1. 
13
To methyl 3-(4-(trifluoromethyl)phenyl)bicyclo[1.1.1]pentane-1-carboxylate (1.3 g, 4.81 mmol) in 1,4-dioxane (10 mL) was added lithium hydroxide (9.62 mL, 9.62 mmol). This was stirred at ambient temperature for 3h. To the reaction was added 2M HCl(aq) (5 mL) and ethyl acetate (30 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (3 x 10 mL). The organic layers were combined and evaporated under reduced pressure to give 3-(4-(trifluoromethyl)phenyl)bicyclo[1. 
